Company / Current Liabilities
Corcept Therapeutics Incorporated Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$166.1M
FY2025
5-year range
$47.5M / $166.1M
FY2021-FY2025
Trend
+18.0%
vs FY2024
Sector context
#65 of 213
Health Care
What the data says
At $166M, Corcept Therapeutics Incorporated's current liabilities ranks #149 of 213 in the Health Care sector. Current Liabilities has increased for 9 consecutive years, from $27M in FY2016 to $166M in FY2025.
Based on SEC 10-K filings.
$166M in FY2025 with a 5-year CAGR of +28.5%.
Increased from $105M to $166M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +31.8%
- 5-Year CAGR
- +28.5%
- 10-Year CAGR
- -
Sector benchmark
#149 of 213 in Health CareTop 69% of 213This company $166.1M Sector average $1.6B
▼
-89.5% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's current liabilities has grown for 9 consecutive years.
- 5-year CAGR of +28.5%, indicating consistent growth.
- In FY2025, current liabilities increased 18.0% year-over-year.
- Ranks #65 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $166.1M | +18.0% |
| FY2024 | $140.8M | +34.7% |
| FY2023 | $104.5M | +44.2% |
| FY2022 | $72.5M | +52.5% |
| FY2021 | $47.5M | +0.1% |
| FY2020 | $47.5M | +22.3% |
| FY2019 | $38.8M | +9.2% |
| FY2018 | $35.6M | +20.3% |
| FY2017 | $29.6M | +8.0% |
| FY2016 | $27.4M | +31.1% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026